Study of Semaglutide Treatment Effects on Kidney and Heart Health in Adults with Type 2 Diabetes and Chronic Kidney Disease in China

What This Trial Is About

Researchers are evaluating the effects of the medicine semaglutide on kidney and heart health in adults who have type 2 diabetes and chronic kidney disease. The study aims to understand how semaglutide, given as a weekly injection under the skin, affects these conditions and whether it is safe to use in this population. This is a Phase 4 clinical trial lasting about 60 to 172 weeks. Participants will receive semaglutide through a subcutaneous injection once every week. The study monitors the time to the first occurrence of significant kidney function decline, kidney failure, kidney-related death, or cardiovascular death. Secondary outcomes include changes in kidney function measures, urinary albumin levels, blood sugar control, cardiovascular events, and safety events such as severe low blood sugar episodes. Throughout the study, participants will be regularly assessed for kidney and heart function using laboratory tests like estimated glomerular filtration rate eGFR, urine albumin-to-creatinine ratio, and glycated hemoglobin HbA1c. Researchers will track serious adverse events and episodes of severe hypoglycemia. The study involves ongoing monitoring from baseline up to about 169 weeks, allowing detailed evaluation of both health outcomes and treatment safety.

A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China